Net specialty spend reached $1,251 PMPY in 2025, driven primarily by rising utilization and member penetration, rather than ...

A randomized, open-label comparison in 31 children (mostly cerebral palsy) evaluated VR plus nitrous oxide versus standard distraction approaches during botulinum toxin injections. Pain scores ...

Require each hospital and care provider to post a single commercial (private insurance) price for each care location, expressed as a simple multiple of the price Medicare pays.

CMS will terminate the Part D premium stabilization subsidies for standalone PDPs in 2027, citing mature sponsor pricing under IRA benefit redesign and a return to “traditional market conditions.” ...

Simtriyo’s mechanism combines norepinephrine/dopamine augmentation with serotonin modulation, expanding beyond traditional stimulant and selective nonstimulant approaches for heterogeneous ADHD ...

CAPTIVATE observed zero HIV acquisitions with CAB LA PrEP, alongside 98% persistence and robust on-time dosing (92% for second initiation injections; 82% for continuation injections). Switching ...

Questions about price and access hover over the positive results for a weekly HIV treatment pill that combines Merck’s islatravir and Gilead’s lenacapavir. Prospects for a weekly pill for HIV ...

LATA provided the first randomized adolescent comparison of Cabenuva versus standard oral ART, enrolling 476 virally suppressed participants across Kenya, South Africa, Uganda, and Zimbabwe. Confirmed ...

Raphael J. Landovitz, M.D., of UCLA says surveillance gaps, Medicaid nonexpansion states and injectable pricing are stalling U.S. PrEP uptake. Asked whether increased PrEP uptake in the U.S. is a slow ...

AVAC Executive Director Mitchell Warren says HIV prevention science has never been stronger, even as funding cuts have left program infrastructure badly weakened. HIV prevention science has never been ...

Raphael J. Landovitz, M.D., says rare lenacapavir breakthrough infections raise new questions about how often patients need testing between PrEP doses. Rare breakthrough HIV infections in people ...